New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Antidepressant dispensing to adolescents and young adults surges during pandemic

Antidepressant dispensing to adolescents and young adults surges during pandemic

by University of MichiganCredit: Pixabay/CC0 Public DomainAntidepressant dispensing to adolescents and young adults increased sharply after the COVID-19 pandemic began—particularly among females—
Psychiatry & Mental Health May 07,2024
Antidepressant dispensing to adolescents and young adults surges during pandemic

Antidepressant dispensing to adolescents and young adults surges during pandemic

by University of MichiganCredit: Pixabay/CC0 Public DomainAntidepressant dispensing to adolescents and young adults increased sharply after the COVID-19 pandemic began—particularly among females—
Psychiatry & Mental Health May 07,2024
Seniors, FDA has 5 medication tips to keep you safe

Seniors, FDA has 5 medication tips to keep you safe

by Dennis ThompsonWhen settling into your senior years, you need to be especially careful when taking medicines, herbal remedies and supplements, the U.S. Food and Drug Administration says.That's
Breakthroughs May 07,2024
Seniors, FDA has 5 medication tips to keep you safe

Seniors, FDA has 5 medication tips to keep you safe

by Dennis ThompsonWhen settling into your senior years, you need to be especially careful when taking medicines, herbal remedies and supplements, the U.S. Food and Drug Administration says.That's
Breakthroughs May 07,2024
Sandalwood oil by-product found to prevent prostate cancer development in mice

Sandalwood oil by-product found to prevent prostate cancer development in mice

by Florida Atlantic UniversityGraphical abstract. Credit:Phytomedicine Plus(2024). DOI: 10.1016/j.phyplu.2024.100523Extracted from the core of sandalwood trees (santalum album tree),
Oncology May 07,2024
Sandalwood oil by-product found to prevent prostate cancer development in mice

Sandalwood oil by-product found to prevent prostate cancer development in mice

by Florida Atlantic UniversityGraphical abstract. Credit:Phytomedicine Plus(2024). DOI: 10.1016/j.phyplu.2024.100523Extracted from the core of sandalwood trees (santalum album tree),
Oncology May 07,2024
Efficacy of electronic cigarettes found to be noninferior to varenicline

Efficacy of electronic cigarettes found to be noninferior to varenicline

by Elana GotkineFor smokers who are motivated to quit, the quit rate is noninferior for electronic cigarettes (ECs) versus varenicline and is higher for ECs than nicotine replacement therapy (NRT) in
Breakthroughs May 07,2024
Efficacy of electronic cigarettes found to be noninferior to varenicline

Efficacy of electronic cigarettes found to be noninferior to varenicline

by Elana GotkineFor smokers who are motivated to quit, the quit rate is noninferior for electronic cigarettes (ECs) versus varenicline and is higher for ECs than nicotine replacement therapy (NRT) in
Breakthroughs May 07,2024
Trial data underpins FDA approval of omalizumab for food allergy

Trial data underpins FDA approval of omalizumab for food allergy

by NIH/National Institute of Allergy and Infectious DiseasesCredit: Unsplash/CC0 Public DomainToday's Food and Drug Administration approval of a supplemental biologics license for the monoclo
Immunology & Rheumatology May 07,2024
Trial data underpins FDA approval of omalizumab for food allergy

Trial data underpins FDA approval of omalizumab for food allergy

by NIH/National Institute of Allergy and Infectious DiseasesCredit: Unsplash/CC0 Public DomainToday's Food and Drug Administration approval of a supplemental biologics license for the monoclo
Immunology & Rheumatology May 07,2024
Q&A: Should heart patients consider taking weight loss medications?

Q&A: Should heart patients consider taking weight loss medications?

by Noah Fromson,University of MichiganCredit: Unsplash/CC0 Public DomainOver the last year, prescriptions for medications that can accelerate weight loss in people with diabetes or without it ha
Q & A May 07,2024
Q&A: Should heart patients consider taking weight loss medications?

Q&A: Should heart patients consider taking weight loss medications?

by Noah Fromson,University of MichiganCredit: Unsplash/CC0 Public DomainOver the last year, prescriptions for medications that can accelerate weight loss in people with diabetes or without it ha
Q & A May 07,2024
New study lists potentially dangerous drugs in Australian health care

New study lists potentially dangerous drugs in Australian health care

by RMIT University'Potentially inappropriate medicines' (PIMs) include ibuprofen and codeine - pictured. Credit: RMIT University / Ant BragagliaResearchers have developed an Australian-fi
Breakthroughs May 07,2024
New study lists potentially dangerous drugs in Australian health care

New study lists potentially dangerous drugs in Australian health care

by RMIT University'Potentially inappropriate medicines' (PIMs) include ibuprofen and codeine - pictured. Credit: RMIT University / Ant BragagliaResearchers have developed an Australian-fi
Breakthroughs May 07,2024
Evaluation of ruxolitinib, a JAK inhibitor, in multiple myeloma

Evaluation of ruxolitinib, a JAK inhibitor, in multiple myeloma

by Impact Journals LLCRuxolitinib exerts its anti-myeloma effects through several mechanisms. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28547A new research perspective titled &quot
Oncology May 07,2024
Evaluation of ruxolitinib, a JAK inhibitor, in multiple myeloma

Evaluation of ruxolitinib, a JAK inhibitor, in multiple myeloma

by Impact Journals LLCRuxolitinib exerts its anti-myeloma effects through several mechanisms. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28547A new research perspective titled &quot
Oncology May 07,2024
Q&A: COVID rebound can happen whether or not you take Paxlovid

Q&A: COVID rebound can happen whether or not you take Paxlovid

by Aliza Rosen,Johns Hopkins University Bloomberg School of Public HealthCredit: Andrea Piacquadio from PexelsWhat initially was referred to as "Paxlovid rebound"—a return of COVID sym
Q & A May 07,2024
Q&A: COVID rebound can happen whether or not you take Paxlovid

Q&A: COVID rebound can happen whether or not you take Paxlovid

by Aliza Rosen,Johns Hopkins University Bloomberg School of Public HealthCredit: Andrea Piacquadio from PexelsWhat initially was referred to as "Paxlovid rebound"—a return of COVID sym
Q & A May 07,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com